Global market

  • 50 milion people in the world and 3 million people in Europe are affected by inflammatory bowel disease (IBD), which has a direct healthcare cost of 4.6 to 5.6 billion euros per year.
  • Diagnosis of IBD such as Crohn’s disease and ulcerative colitis tends to be slow and based on vague clinical parameters.
  • In addition to IBD, irritable bowel syndrome (IBS) is one of the 10 most difficult diseases to identify according to Fleming’s list.
  • It is estimated that up to 45% of patients wait more than one year for a diagnosis for these pathologies, whilst up to 17% wait more than five years. 


Our proposal

IBD and IBS are characterised by intermittent periods of flare-ups and no activity or remission, complicating follow-up with aggressive treatment and invasive techniques.

Thanks to our disruptive RAID-CD, an efficient, rapid and non-invasive diagnosis can be carried out by way of a stool test with high sensitivity and specificity to distinguish between Crohn’s disease, ulcerative colitis and irritable bowel syndrome without the need for a colonoscopy.

Treatment prediction: through the specific bacterial signature of RAID-CD we are able to determine its response before patient start treatment what helps to efficiently deal with therapeutic pauta.

RAID-CD will significantly improve the quality of life of patients.

Healthio 2018

Healthio 2018

By goodgut.eu, On 17 de October de 2018

GoodGut is to present its non-invasive tests to support the diagnosis and treatment ...

2019 InSiGHT Meeting

2019 InSiGHT Meeting

By goodgut.eu, On 20 de March de 2019

The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) and the New Zealand Society ...